Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Uniqure N.V. (Nasdaq: QURE)

uniQure is a world leader in the development of human gene based therapies. uniQure product pipeline of gene therapy products in development comprise hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows uniQure to pursue its strategy of focusing on this sector of the industry. uniQure's largest shareholders are Forbion Capital Partners and Gilde Healthcare, two of the leading life sciences venture capital firms in the Netherlands. *

 

Period Start 2014-04-09 renamed before
  Group Uniqure (Group)
  Predecessor Uniqure B.V.
Products Industry gene therapy
  Industry 2 Glybera®
Persons Person Kapusta, Matthew (Uniqure 201612– CEO before interim CEO before CFO before AngioDynamics + Smith & Nephew Orthopaedics)
  Person 2 Astley-Sparke, Philip (Forbion 201209– Venture Partner before Amgen + BioVex CEO since 2005 + JP Morgan)
     
Region Region Amsterdam
  Country Netherlands
  Street 61 Meibergdreef
  City 1105 BA Amsterdam
  Tel +31-20-566-7394
    Address record changed: 2014-05-08
     
Basic data Employees n. a.
  Currency EUR
  Annual sales 11,284,000 (revenues, total, consolidated (2018) 2018-12-31)
  Profit -83,304,000 (2018-12-31)
  Cash 208,800,000 (2019-03-31)
     
    * Document for �About Section�: Uniqure B.V.. (11/2/12). "Press Release: Uniqure’s Glybera First Gene Therapy Approved by European Commission". Amsterdam.
     
   
Record changed: 2019-05-22

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Uniqure (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top